A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics in Healthy Male Japanese (Single-blind, Randomized, Placebo-controlled) and Caucasian (Open-label) Subjects After Single and Once Daily Multiple Oral Doses of D5884
Phase of Trial: Phase I
Latest Information Update: 30 May 2016
At a glance
- Drugs Omega-3 carboxylic acids (Primary)
- Indications Cardiovascular disorders; Hypertriglyceridaemia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 09 Nov 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 20 Oct 2014 Planned number of patients changed from 48 to 24, as reported by ClinicalTrials.gov.
- 19 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.